{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T13:47:52Z","timestamp":1790689672951,"version":"4.1.0"},"reference-count":80,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,2,1]],"date-time":"2022-02-01T00:00:00Z","timestamp":1643673600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2022,2]]},"DOI":"10.1016\/j.neuropharm.2021.108884","type":"journal-article","created":{"date-parts":[[2021,11,13]],"date-time":"2021-11-13T23:50:08Z","timestamp":1636847408000},"page":"108884","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":19,"special_numbering":"C","title":["The novel dual-mechanism Kv7 potassium channel\/TSPO receptor activator GRT-X is more effective than the Kv7 channel opener retigabine in the 6-Hz refractory seizure mouse model"],"prefix":"10.1016","volume":"203","author":[{"given":"Petra","family":"Bloms-Funke","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marion","family":"Bankstahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4735-4490","authenticated-orcid":false,"given":"Jens","family":"Bankstahl","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christa","family":"Kneip","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"Schr\u00f6der","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wolfgang","family":"L\u00f6scher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2021.108884_bib1","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1021\/ml200053x","article-title":"N-pyridyl and pyrimidine benzamides as KCNQ2\/Q3 potassium channel openers for the treatment of epilepsy","volume":"2","author":"Amato","year":"2011","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.neuropharm.2021.108884_bib2","series-title":"Australian Public Assessment Report for Retigabine","author":"Australian Government","year":"2013"},{"key":"10.1016\/j.neuropharm.2021.108884_bib3","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/j.neuro.2011.12.011","article-title":"Striking differences in proconvulsant-induced alterations of seizure threshold in two rat models","volume":"33","author":"Bankstahl","year":"2012","journal-title":"Neurotoxicology"},{"key":"10.1016\/j.neuropharm.2021.108884_bib4","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1016\/j.eplepsyres.2013.09.014","article-title":"Pilocarpine-induced epilepsy in mice alters seizure thresholds and the efficacy of antiepileptic drugs in the 6-Hertz psychomotor seizure model","volume":"107","author":"Bankstahl","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2021.108884_bib5","first-page":"225","article-title":"Neuronal potassium channel openers in the management of epilepsy: role and potential of retigabine","volume":"2","author":"Barrese","year":"2010","journal-title":"Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108884_bib6","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1146\/annurev-pharmtox-010617-052912","article-title":"KCNQ-encoded potassium channels as therapeutic targets","volume":"58","author":"Barrese","year":"2018","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"10.1016\/j.neuropharm.2021.108884_bib7","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/S0920-1211(01)00302-3","article-title":"Pharmacological characterization of the 6 Hz psychomotor seizure model of partial epilepsy","volume":"47","author":"Barton","year":"2001","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2021.108884_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.eplepsyres.2008.09.005","article-title":"Progress report on new antiepileptic drugs: a summary of the Ninth Eilat Conference (EILAT IX)","volume":"83","author":"Bialer","year":"2009","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2021.108884_bib9","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1038\/nrd2997","article-title":"Key factors in the discovery and development of new antiepileptic drugs","volume":"9","author":"Bialer","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2021.108884_bib10","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.eplepsyres.2012.10.001","article-title":"Progress report on new antiepileptic drugs: a summary of the Eleventh Eilat Conference (EILAT XI)","volume":"103","author":"Bialer","year":"2013","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2021.108884_bib11","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.eplepsyres.2015.01.001","article-title":"Progress report on new antiepileptic drugs: a summary of the Twelfth Eilat Conference (EILAT XII)","volume":"111","author":"Bialer","year":"2015","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2021.108884_bib12","doi-asserted-by":"crossref","first-page":"2340","DOI":"10.1111\/epi.16725","article-title":"Progress report on new antiepileptic drugs: a summary of the Fifteenth Eilat Conference on New Antiepileptic Drugs and Devices (EILAT XV). I. Drugs in preclinical and early clinical development","volume":"61","author":"Bialer","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2021.108884_bib13","doi-asserted-by":"crossref","first-page":"1629","DOI":"10.1096\/fj.14-269043","article-title":"Translating dosages from animal models to human clinical trials--revisiting body surface area scaling","volume":"29","author":"Blanchard","year":"2015","journal-title":"Faseb. J."},{"key":"10.1016\/j.neuropharm.2021.108884_bib14","article-title":"A novel dual mode-of-action anti-hyperalgesic compound in ratswhich is neuroprotective and promotes neuroregeneration","author":"Bloms-Funke","year":"2021","journal-title":"Eur. J. Pharmacol. submitted."},{"key":"10.1016\/j.neuropharm.2021.108884_bib15","doi-asserted-by":"crossref","first-page":"1182","DOI":"10.1111\/bph.12065","article-title":"The new KCNQ2 activator 4-Chlor-N-(6-chlor-pyridin-3-yl)-benzamid displays anticonvulsant potential","volume":"168","author":"Boehlen","year":"2013","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108884_bib16","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1111\/j.1476-5381.2009.00111.x","article-title":"Neural KCNQ (Kv7) channels","volume":"156","author":"Brown","year":"2009","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108884_bib17","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1042\/BST20150028","article-title":"Targeting the 18-kDa translocator protein: recent perspectives for neuroprotection","volume":"43","author":"Da Pozzo","year":"2015","journal-title":"Biochem. Soc. Trans."},{"key":"10.1016\/j.neuropharm.2021.108884_bib18","doi-asserted-by":"crossref","first-page":"18024","DOI":"10.1038\/nrdp.2018.24","volume":"4","author":"Devinsky","year":"2018","journal-title":"Epilepsy. Nat. Rev. Dis. Primers."},{"key":"10.1016\/j.neuropharm.2021.108884_bib19","doi-asserted-by":"crossref","first-page":"2684","DOI":"10.1111\/j.1476-5381.2011.01733.x","article-title":"Role of neurosteroids in the anticonvulsant activity of midazolam","volume":"165","author":"Dhir","year":"2012","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108884_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.4172\/Neuropsychiatry.1000175","article-title":"Current insight into the role of voltage-gated potassiumion channel 7 (Kv7) channels: an emerging therapy target against epilepsy","volume":"7","author":"Diao","year":"2017","journal-title":"Neuropsychiatry"},{"key":"10.1016\/j.neuropharm.2021.108884_bib21","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1177\/00912700222011210","article-title":"Multiple-dose, linear, dose-proportional pharmacokinetics of retigabine in healthy volunteers","volume":"42","author":"Ferron","year":"2002","journal-title":"J. Clin. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108884_bib22","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1111\/j.2042-7158.1989.tb06395.x","article-title":"A simple intravenous infusion method in rodents for determining the potency of anticonvulsants acting through GABAergic mechanisms","volume":"41","author":"Green","year":"1989","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108884_bib23","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1007\/s00018-016-2359-y","article-title":"Modulation of Kv7 channels and excitability in the brain","volume":"74","author":"Greene","year":"2017","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.neuropharm.2021.108884_bib24","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1021\/acs.chemrestox.8b00313","article-title":"An investigation into retigabine (ezogabine) associated dyspigmentation in rat eyes by MALDI imaging mass spectrometry","volume":"32","author":"Groseclose","year":"2019","journal-title":"Chem. Res. Toxicol."},{"key":"10.1016\/j.neuropharm.2021.108884_bib25","doi-asserted-by":"crossref","first-page":"173440","DOI":"10.1016\/j.ejphar.2020.173440","article-title":"In vitro and in vivo characterization of Lu AA41178: a novel, brain penetrant, pan-selective Kv7 potassium channel opener with efficacy in preclinical models of epileptic seizures and psychiatric disorders","volume":"887","author":"Grupe","year":"2020","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108884_bib26","doi-asserted-by":"crossref","first-page":"2329","DOI":"10.1111\/epi.16718","article-title":"Cenobamate (XCOPRI\u00ae): can preclinical and clinical evidence provide insight into its mechanism of action?","volume":"61","author":"Guignet","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2021.108884_bib27","doi-asserted-by":"crossref","first-page":"44","DOI":"10.1016\/j.pharmthera.2018.09.003","article-title":"TSPO in diverse CNS pathologies and psychiatric disease: a critical review and a way forward","volume":"194","author":"Guilarte","year":"2019","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2021.108884_bib28","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1111\/j.1528-1167.2011.03365.x","article-title":"The mechanism of action of retigabine (ezogabine), a first-in-class K+ channel opener for the treatment of epilepsy","volume":"53","author":"Gunthorpe","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2021.108884_bib29","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1016\/j.ajog.2010.06.011","article-title":"Steroid profiling in preeclamptic women: evidence for aromatase deficiency","volume":"203","author":"Hertig","year":"2010","journal-title":"Am. J. Obstet. Gynecol."},{"key":"10.1016\/j.neuropharm.2021.108884_bib30","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1038\/35036198","article-title":"Neuronal KCNQ potassium channels: physiology and role in disease","volume":"1","author":"Jentsch","year":"2000","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108884_bib31","doi-asserted-by":"crossref","first-page":"8829","DOI":"10.1523\/JNEUROSCI.5176-14.2015","article-title":"Potent KCNQ2\/3-specific channel activator suppresses in vivo epileptic activity and prevents the development of tinnitus","volume":"35","author":"Kalappa","year":"2015","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108884_bib32","doi-asserted-by":"crossref","first-page":"1894","DOI":"10.1007\/s11064-017-2275-z","article-title":"National institute of neurological disorders and stroke (NINDS) epilepsy therapy screening program (ETSP)","volume":"42","author":"Kehne","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2021.108884_bib33","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1124\/mol.115.103200","article-title":"Synthesis and evaluation of potent KCNQ2\/3-specific channel activators","volume":"89","author":"Kumar","year":"2016","journal-title":"Mol. Pharmacol."},{"issue":"Suppl. 4","key":"10.1016\/j.neuropharm.2021.108884_bib34","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1111\/j.1528-1167.2001.00002.x","article-title":"Animal models used in the screening of antiepileptic drugs","volume":"42","author":"Kupferberg","year":"2001","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2021.108884_bib35","series-title":"Substituted 2-Oxo-And 2-Thioxo-Dihydroquinoline-3-Carboxamides as KCNQ2\/3 Modulators. Patent Family Based on WO 2012\/025239","author":"K\u00fchnert","year":"2012"},{"key":"10.1016\/j.neuropharm.2021.108884_bib36","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1111\/j.1528-1167.2011.03364.x","article-title":"The spectrum of anticonvulsant efficacy of retigabine (ezogabine) in animal models: implications for clinical use","volume":"53","author":"Large","year":"2012","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2021.108884_bib37","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1016\/0024-3205(83)90794-4","article-title":"Differentiation between two ligands for peripheral benzodiazepine binding sites, [3H]RO5-4864 and [3H]PK 11195, by thermodynamic studies","volume":"33","author":"Le Fur","year":"1983","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2021.108884_bib38","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1111\/epi.12893","article-title":"Genetic background of mice strongly influences treatment resistance in the 6 Hz seizure model","volume":"56","author":"Leclercq","year":"2015","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2021.108884_bib39","doi-asserted-by":"crossref","first-page":"2821","DOI":"10.1021\/acs.biochem.6b00142","article-title":"Translocator protein 18 kDa (TSPO): an old protein with new functions?","volume":"55","author":"Li","year":"2016","journal-title":"Biochemistry"},{"key":"10.1016\/j.neuropharm.2021.108884_bib40","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.1194\/jlr.M400244-JLR200","article-title":"Novel lipoidal derivatives of pregnenolone and dehydroepiandrosterone and absence of their sulfated counterparts in rodent brain","volume":"45","author":"Liere","year":"2004","journal-title":"J. Lipid Res."},{"key":"10.1016\/j.neuropharm.2021.108884_bib41","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/0920-1211(88)90054-X","article-title":"Which animal models should be used in the search for new antiepileptic drugs? A proposal based on experimental and clinical considerations","volume":"2","author":"L\u00f6scher","year":"1988","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2021.108884_bib80","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0022-3565(25)03549-9","article-title":"A simplified method of evaluating dose-effect experiments","volume":"96","author":"Litchfield","year":"1949","journal-title":"J. Pharmacol.Exp.Ther."},{"key":"10.1016\/j.neuropharm.2021.108884_bib42","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/j.seizure.2011.01.003","article-title":"Critical review of current animal models of seizures and epilepsy used in the discovery and development of new antiepileptic drugs","volume":"20","author":"L\u00f6scher","year":"2011","journal-title":"Seizure"},{"key":"10.1016\/j.neuropharm.2021.108884_bib43","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eplepsyres.2016.05.016","article-title":"Fit for purpose application of currently existing animal models in the discovery of novel epilepsy therapies","volume":"126","author":"L\u00f6scher","year":"2016","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2021.108884_bib44","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1007\/s40263-016-0384-x","article-title":"Synaptic vesicle glycoprotein 2A ligands in the treatment of epilepsy and beyond","volume":"30","author":"L\u00f6scher","year":"2016","journal-title":"CNS Drugs"},{"key":"10.1016\/j.neuropharm.2021.108884_bib45","doi-asserted-by":"crossref","first-page":"1873","DOI":"10.1007\/s11064-017-2222-z","article-title":"Animal models of seizures and epilepsy: past, present, and future role for the discovery of antiseizure drugs","volume":"42","author":"L\u00f6scher","year":"2017","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.neuropharm.2021.108884_bib46","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.yebeh.2017.05.040","article-title":"The relevance of inter- and intrastrain differences in mice and rats and their implications for models of seizures and epilepsy","volume":"73","author":"L\u00f6scher","year":"2017","journal-title":"Epilepsy Behav."},{"key":"10.1016\/j.neuropharm.2021.108884_bib47","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1124\/pr.120.019539","article-title":"Drug resistance in epilepsy: clinical impact, potential mechanisms, and new innovative treatment options","volume":"72","author":"L\u00f6scher","year":"2020","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2021.108884_bib48","doi-asserted-by":"crossref","first-page":"596","DOI":"10.1111\/epi.16832","article-title":"The ups and downs of alkyl-carbamates in epilepsy therapy: how does cenobamate differ?","volume":"62","author":"L\u00f6scher","year":"2021","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2021.108884_bib49","doi-asserted-by":"crossref","first-page":"366","DOI":"10.2174\/1389557515666150324122642","article-title":"The translocator protein 18 kDa (TSPO) and its role in mitochondrial biology and psychiatric disorders","volume":"15","author":"Milenkovic","year":"2015","journal-title":"Mini Rev. Med. Chem."},{"key":"10.1016\/j.neuropharm.2021.108884_bib50","doi-asserted-by":"crossref","first-page":"483","DOI":"10.1111\/j.1528-1157.1986.tb03572.x","article-title":"Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats","volume":"27","author":"Miller","year":"1986","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2021.108884_bib51","doi-asserted-by":"crossref","first-page":"27","DOI":"10.4103\/0976-0105.177703","article-title":"A simple practice guide for dose conversion between animals and human","volume":"7","author":"Nair","year":"2016","journal-title":"J. Basic Clin. Pharm."},{"key":"10.1016\/j.neuropharm.2021.108884_bib52","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1038\/nn.3933","article-title":"Pathway-driven discovery of epilepsy genes","volume":"18","author":"Noebels","year":"2015","journal-title":"Nat. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108884_bib53","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1016\/j.neulet.2009.08.071","article-title":"The KCNQ2\/3 selective channel opener ICA-27243 binds to a novel voltage-sensor domain site","volume":"465","author":"Padilla","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2021.108884_bib54","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1016\/S1474-4422(12)70153-9","article-title":"Adverse effects of antiepileptic drugs","volume":"11","author":"Perucca","year":"2012","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.neuropharm.2021.108884_bib55","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.pbb.2015.10.005","article-title":"Translocator protein mediates the anxiolytic and antidepressant effects of midazolam","volume":"139","author":"Qiu","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2021.108884_bib56","doi-asserted-by":"crossref","first-page":"38","DOI":"10.3389\/fendo.2011.00038","article-title":"Role of anticonvulsant and antiepileptogenic neurosteroids in the pathophysiology and treatment of epilepsy","volume":"2","author":"Reddy","year":"2011","journal-title":"Front Endocrinol. (Lausanne)"},{"key":"10.1016\/j.neuropharm.2021.108884_bib57","doi-asserted-by":"crossref","first-page":"12554","DOI":"10.18632\/oncotarget.15261","article-title":"Targeting Kv7 channels in pain pathways","volume":"8","author":"Rivera-Arconada","year":"2017","journal-title":"Oncotarget"},{"key":"10.1016\/j.neuropharm.2021.108884_bib58","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S0163-7258(01)00116-4","article-title":"KCNQ potassium channels: physiology, pathophysiology, and pharmacology","volume":"90","author":"Robbins","year":"2001","journal-title":"Pharmacol. Ther."},{"issue":"Suppl. 6","key":"10.1016\/j.neuropharm.2021.108884_bib59","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/epi.12289","article-title":"Neuroactive steroids for the treatment of status epilepticus","volume":"54","author":"Rogawski","year":"2013","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2021.108884_bib60","doi-asserted-by":"crossref","DOI":"10.1101\/cshperspect.a022780","article-title":"Mechanisms of action of antiseizure drugs and the ketogenic diet","author":"Rogawski","year":"2016","journal-title":"Cold Spring Harb. Perspect. Med."},{"key":"10.1016\/j.neuropharm.2021.108884_bib61","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/0920-1211(95)00101-8","article-title":"D-23129: a new anticonvulsant with a broad spectrum activity in animal models of epileptic seizures","volume":"23","author":"Rostock","year":"1996","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2021.108884_bib62","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.eplepsyres.2010.09.002","article-title":"Comparative anticonvulsant efficacy in the corneal kindled mouse model of partial epilepsy: correlation with other seizure and epilepsy models","volume":"92","author":"Rowley","year":"2010","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2021.108884_bib63","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0014-2999(97)01249-1","article-title":"The new anticonvulsant retigabine (D-23129) acts as an opener of K+ channels in neuronal cells","volume":"336","author":"Rundfeldt","year":"1997","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2021.108884_bib64","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1038\/nrd3295","article-title":"Translocator protein (18 kDa) (TSPO) as a therapeutic target for neurological and psychiatric disorders","volume":"9","author":"Rupprecht","year":"2010","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2021.108884_bib65","first-page":"173","article-title":"Species differences in the pharmacokinetic parameters of cytochrome P450 probe substrates between experimental animals, such as mice, rats, dogs, monkeys, and microminipigs, and humans","volume":"5","author":"Sakei","year":"2014","journal-title":"J. Drug Metabol. Toxicol."},{"key":"10.1016\/j.neuropharm.2021.108884_bib66","doi-asserted-by":"crossref","first-page":"79","DOI":"10.1016\/j.pneurobio.2013.09.003","article-title":"The role of allopregnanolone in depression and anxiety","volume":"113","author":"Schule","year":"2014","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2021.108884_bib67","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1111\/j.1528-1157.1994.tb02459.x","article-title":"Topiramate - preclinical evaluation of a structurally novel anticonvulsant","volume":"35","author":"Shank","year":"1994","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2021.108884_bib68","doi-asserted-by":"crossref","first-page":"31","DOI":"10.4137\/JCNSD.S9299","article-title":"Efficacy of retigabine in adjunctive treatment of partial onset seizures in adults","volume":"5","author":"Splinter","year":"2013","journal-title":"J. Cent. Nerv. Syst. Dis."},{"key":"10.1016\/j.neuropharm.2021.108884_bib69","doi-asserted-by":"crossref","first-page":"729","DOI":"10.1038\/nrd3561","article-title":"Ezogabine (retigabine)","volume":"10","author":"Stafstrom","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2021.108884_bib70","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/j.eplepsyres.2007.03.004","article-title":"Lacosamide, a novel anti-convulsant drug, shows efficacy with a wide safety margin in rodent models for epilepsy","volume":"74","author":"St\u00f6hr","year":"2007","journal-title":"Epilepsy Res."},{"key":"10.1016\/j.neuropharm.2021.108884_bib71","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1111\/j.1528-1157.1986.tb03497.x","article-title":"Comparative anticonvulsant activity and neurotoxicity of felbamate and four prototype antiepileptic drugs in mice and rats","volume":"27","author":"Swinyard","year":"1986","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2021.108884_bib72","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1111\/epi.16531","article-title":"Evaluation of subchronic administration of antiseizure drugs in spontaneously seizing rats","volume":"61","author":"Thomson","year":"2020","journal-title":"Epilepsia"},{"key":"10.1016\/j.neuropharm.2021.108884_bib73","doi-asserted-by":"crossref","first-page":"16788","DOI":"10.1523\/JNEUROSCI.4101-10.2010","article-title":"Midazolam inhibits hippocampal long-term potentiation and learning through dual central and peripheral benzodiazepine receptor activation and neurosteroidogenesis","volume":"30","author":"Tokuda","year":"2010","journal-title":"J. Neurosci."},{"key":"10.1016\/j.neuropharm.2021.108884_bib74","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.pbb.2005.11.013","article-title":"The anxiolytic etifoxine activates the peripheral benzodiazepine receptor and increases the neurosteroid levels in rat brain","volume":"82","author":"Verleye","year":"2005","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2021.108884_bib75","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.seizure.2016.11.030","article-title":"Epilepsy-associated genes","volume":"44","author":"Wang","year":"2017","journal-title":"Seizure"},{"key":"10.1016\/j.neuropharm.2021.108884_bib76","doi-asserted-by":"crossref","first-page":"107811","DOI":"10.1016\/j.neuropharm.2019.107811","article-title":"The current approach of the epilepsy therapy screening program contract site for identifying improved therapies for the treatment of pharmacoresistant seizures in epilepsy","volume":"166","author":"Wilcox","year":"2020","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2021.108884_bib77","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1016\/j.seizure.2018.10.012","article-title":"Progesterone, 5a-dihydropogesterone and allopregnanolone's effects on seizures: a review of animal and clinical studies","volume":"63","author":"Wu","year":"2018","journal-title":"Seizure"},{"key":"10.1016\/j.neuropharm.2021.108884_bib78","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1038\/aps.2015.142","article-title":"Novel KCNQ2 channel activators discovered using fluorescence-based and automated patch-clamp-based high-throughput screening techniques","volume":"37","author":"Yue","year":"2016","journal-title":"Acta Pharmacol. Sin."},{"key":"10.1016\/j.neuropharm.2021.108884_bib79","doi-asserted-by":"crossref","first-page":"9154","DOI":"10.1096\/fj.201802848RR","article-title":"Electrophysiological and pharmacological characterization of a novel and potent neuronal Kv7 channel opener SCR2682 for antiepilepsy","volume":"33","author":"Zhang","year":"2019","journal-title":"Faseb. J."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821004391?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390821004391?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:16:01Z","timestamp":1758438961000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390821004391"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2]]},"references-count":80,"alternative-id":["S0028390821004391"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108884","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2022,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The novel dual-mechanism Kv7 potassium channel\/TSPO receptor activator GRT-X is more effective than the Kv7 channel opener retigabine in the 6-Hz refractory seizure mouse model","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2021.108884","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108884"}}